Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30726441 | 0.77 | IRAK4 (0.47) | — | |
| SCHEMBL27039665 | 0.71 | IRAK4 (0.38) | — | |
| SCHEMBL15578958 | 0.71 | EGLN1 (0.70) | EGLN1ALKBH1 | |
| SCHEMBL25344539 | 0.67 | FASN (0.44) | EGLN1 | |
| SCHEMBL28835764 | 0.66 | KDM4E (0.44) | LMNAEGLN1MAPTEGLN2 | |
| SCHEMBL16467115 | 0.66 | EGLN1 (0.48) | LMNAEGLN1MAP4K4EGLN2ALKBH1 | |
| SCHEMBL600130 | 0.65 | MAPT (0.64) | LMNAEGLN1MAPTP4HA1P4HTM | |
| SCHEMBL12309596 | 0.64 | — | — | |
| SCHEMBL23832249 | 0.64 | KDM4C (0.43) | LMNAEGLN1XDHMAP4K4 | |
| SCHEMBL838612 | 0.64 | MGAM (0.57) | SLC22A12XDHMAP4K4EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |